SCHEMBL6185008

SCHEMBL6185008

CC(C)COC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN[C@@H]1CCc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 14/20 0.51
CTSD P07339 9/20 0.51
BACE2 Q9Y5Z0 6/20 0.51
ALDH1A1 P00352 4/20 0.42
HTT P42858 2/20 0.42
KDM4E B2RXH2 3/20 0.42
KMT2A Q03164 2/20 0.41
LMNA P02545 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
MEN1 O00255 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
ADRB2 P07550 1/20 0.41
ADRB1 P08588 1/20 0.41
CYP3A4 P08684 1/20 0.41
ADRB3 P13945 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
PSMB5 P28074 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5222976 0.86 KLK5 (0.53) BACE1CTSDBACE2
SCHEMBL5404137 0.86 KLK5 (0.53) BACE1CTSDBACE2
SCHEMBL5404127 0.86 KLK5 (0.53) BACE1CTSDBACE2
SCHEMBL3357333 0.85 BACE1 (0.55) BACE1CTSDBACE2ALDH1A1HTT
SCHEMBL3357325 0.85 BACE1 (0.55) BACE1CTSDBACE2ALDH1A1HTT
SCHEMBL6111643 0.84 BACE1 (0.56) BACE1CTSDBACE2
SCHEMBL5223062 0.80 BACE1 (0.56) BACE1CTSDBACE2ALDH1A1HTT
SCHEMBL13307719 0.76 BACE1 (0.60) BACE1CTSD
SCHEMBL13307722 0.76 BACE1 (0.60) BACE1CTSD
SCHEMBL3347460 0.76 MAOA (0.46) BACE1CTSDBACE2ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567488-A1 HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE GLAXO GROUP LIMITED (GB) 2005-08-31 EP disclosed
WO-2004050619-A1 HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE GLAXO GROUP LIMITED (GB) 2004-06-17 WO disclosed